Atezolizumab and Bevacizumab with radiation for liver cancer that can't be removed
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding two immunotherapy and anti-angiogenesis drugs (atezolizumab and bevacizumab) to standard photon radiation for people with liver cancer that cannot be surgically removed. It aims to see if this combination can shrink tumors and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with hepatocellular carcinoma (liver cancer) that cannot be removed by surgery.
- Your largest tumor is 15 cm or smaller and the total size of all tumors is less than 20 cm.
- You are 18 years or older.
- You are in generally good health (able to perform daily activities) and have liver function within a certain range.
- You have not had radiation therapy to the liver area before, and you do not have untreated hepatitis B or C.
- You do not have active bleeding, heart disease, or other serious health problems that would interfere with the treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs (atezolizumab and bevacizumab) with or without targeted radiation therapy for liver cancer that has invaded the major blood vessels of the liver. The goal is to see if adding radiation helps shrink tumors or slow the disease.
This trial studies how well atezolizumab and bevacizumab work together with radiation to treat advanced hepatocellular carcinoma (liver cancer) that has spread into the portal vein. It may help shrink or control tumors and improve outcomes, but you must meet several safety and cancer-location criteria.
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
This trial tests a combination of carbon ion radiation therapy with two drugs, atezolizumab and bevacizumab, for people with advanced liver cancer that cannot be surgically removed. The goal is to see if this approach is safe and effective.
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
This early-phase trial tests a treatment plan that combines focused radiation with two medicines—an immunotherapy drug and an anti-angiogenesis drug—to treat hepatocellular carcinoma (liver cancer). It may help shrink tumors or control disease when surgery or ablation can’t be used, and when systemic (whole-body) treatment is needed.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.